Profile data is unavailable for this security.
About the company
Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of products to enhance cancer care. The Company is commercializing NERLYNX, an oral version of neratinib, for the treatment of certain HER2-positive breast cancers. NERLYNX is approved in the United States for two indications: the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer following adjuvant trastuzumab-based therapy and for use in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting. The Company has in-licensed and is responsible for the global development and commercialization of alisertib. It intends to pursue the development of alisertib initially in small cell lung cancer and hormone receptor positive breast cancer.
- Revenue in USD (TTM)212.00m
- Net income in USD36.98m
- Incorporated2010
- Employees172.00
- LocationPuma Biotechnology Inc10880 Wilshire Blvd., Suite 2150LOS ANGELES 90024United StatesUSA
- Phone+1 (424) 248-6500
- Fax+1 (424) 248-6501
- Websitehttps://www.pumabiotechnology.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Coherus Oncology Inc | 83.57m | -187.47m | 258.66m | 161.00 | -- | 2.83 | -- | 3.10 | -1.62 | 1.33 | 0.721 | 0.7551 | 0.1636 | 1.76 | 0.9453 | 366,526.30 | -36.70 | -21.44 | -106.02 | -31.54 | 47.79 | 71.26 | -224.34 | -42.66 | 1.23 | -15.12 | 0.3656 | -- | 3.78 | -5.60 | 111.98 | -20.51 | -- | -- |
| Fennec Pharmaceuticals Inc | 38.79m | -6.94m | 267.76m | 36.00 | -- | -- | -- | 6.90 | -0.2524 | -0.2524 | 1.41 | -0.1601 | 0.7171 | 1.48 | 2.41 | -- | -12.83 | -55.15 | -15.26 | -64.98 | 93.12 | -- | -17.89 | -107.31 | 4.44 | -2.44 | 1.33 | -- | 123.69 | -- | 97.28 | -- | -- | -- |
| Abeona Therapeutics Inc | 400.00k | 82.35m | 278.00m | 136.00 | 4.64 | 1.57 | 3.28 | 695.00 | 1.11 | 1.11 | 0.0073 | 3.27 | 0.0023 | -- | 0.2478 | 2,941.18 | 46.83 | -62.23 | 52.94 | -78.23 | -122.00 | -- | 20,587.50 | -1,824.21 | 9.53 | -- | 0.1034 | -- | -100.00 | -- | -17.62 | -- | -17.78 | -- |
| Lifecore Biomedical Inc | -100.00bn | -100.00bn | 283.62m | 406.00 | -- | -- | -- | -- | -- | -- | -- | 0.9818 | -- | -- | -- | -- | -- | -7.91 | -- | -10.85 | -- | 32.86 | -- | -23.15 | 1.67 | -- | 0.787 | -- | 0.4725 | -4.24 | -575.39 | -- | -12.85 | -- |
| Evolus Inc | 285.82m | -58.56m | 291.69m | 329.00 | -- | -- | -- | 1.02 | -0.9125 | -0.9125 | 4.46 | -0.4441 | 1.27 | 4.09 | 6.01 | 860,912.60 | -26.11 | -37.04 | -36.48 | -57.14 | 65.83 | 65.19 | -20.49 | -51.26 | 1.53 | -2.13 | 1.25 | -- | 31.76 | 50.12 | 18.26 | -- | 1.10 | -- |
| X4 Pharmaceuticals Inc | 33.98m | -95.10m | 311.27m | 143.00 | -- | 1.45 | -- | 9.16 | -10.50 | -10.50 | 2.94 | 2.45 | 0.1989 | 1.75 | 25.37 | 237,615.40 | -55.66 | -55.04 | -65.82 | -63.45 | 83.24 | -- | -279.86 | -6,897.81 | 5.48 | -19.26 | 0.5525 | -- | -- | -- | 62.98 | -- | 111.28 | -- |
| AC Immune SA | 5.64m | -92.66m | 316.22m | 133.00 | -- | 3.93 | -- | 56.11 | -0.9221 | -0.9221 | 0.0561 | 0.8017 | 0.021 | -- | 0.3392 | 42,377.44 | -34.57 | -27.41 | -66.37 | -30.60 | -- | -- | -1,643.94 | -505.58 | -- | -- | 0.0695 | -- | 84.51 | -24.38 | 6.12 | -- | -21.11 | -- |
| Puma Biotechnology Inc | 212.00m | 36.98m | 349.71m | 172.00 | 9.36 | 3.03 | 7.27 | 1.65 | 0.7414 | 0.7414 | 4.23 | 2.29 | 1.00 | 8.06 | 4.81 | 1,232,529.00 | 17.46 | -3.25 | 32.09 | -5.70 | 76.91 | 75.67 | 17.44 | -3.18 | 1.62 | 8.84 | 0.2263 | -- | -2.19 | -3.28 | 40.23 | -- | -28.80 | -- |
| Akebia Therapeutics Inc | 225.07m | -15.91m | 368.86m | 181.00 | -- | 8.86 | -- | 1.64 | -0.0761 | -0.0761 | 0.8951 | 0.1568 | 0.7879 | 2.08 | 4.57 | 1,243,486.00 | -5.57 | -38.92 | -8.55 | -61.07 | 81.89 | 71.93 | -7.07 | -76.49 | 1.80 | 0.7147 | 0.8219 | -- | -17.70 | -13.72 | -33.67 | -- | -65.40 | -- |
| Enanta Pharmaceuticals Inc | 65.32m | -81.89m | 392.04m | 120.00 | -- | 4.46 | -- | 6.00 | -3.84 | -3.84 | 3.06 | 3.03 | 0.1987 | -- | 9.66 | 544,366.70 | -24.91 | -26.15 | -29.71 | -29.36 | -- | -- | -125.36 | -134.68 | -- | -- | 0.6887 | -- | -3.42 | -11.81 | 29.43 | -- | 54.92 | -- |
| Eton Pharmaceuticals Inc | 70.32m | -6.68m | 395.83m | 31.00 | -- | 17.12 | -- | 5.63 | -0.2491 | -0.2491 | 2.63 | 0.8624 | 1.00 | 3.64 | 7.53 | 2,268,258.00 | -9.52 | -27.81 | -17.48 | -37.96 | 51.36 | 68.16 | -9.50 | -38.41 | 1.25 | 0.2114 | 0.5677 | -- | 23.29 | 109.83 | -308.44 | -- | 40.24 | -- |
| Nika Pharmaceuticals Inc | 0.00 | -51.76k | 403.46m | -- | -- | -- | -- | -- | -0.00005 | -0.00005 | 0.00 | -0.0003 | 0.00 | -- | -- | -- | -413.75 | -21,428.06 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -47.74 | -- | -- | -- |
| Invivyd Inc | 50.04m | -59.86m | 448.36m | 99.00 | -- | 3.66 | -- | 8.96 | -0.4736 | -0.4736 | 0.3778 | 0.4341 | 0.3324 | -- | 5.56 | 505,444.40 | -39.76 | -- | -67.24 | -- | 93.34 | -- | -119.63 | -- | -- | -- | 0.00 | -- | -- | -- | 14.46 | -- | -- | -- |
Data as of Feb 06 2026. Currency figures normalised to Puma Biotechnology Inc's reporting currency: US Dollar USD
33.95%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 Dec 2025 | 3.53m | 7.01% |
| BlackRock Fund Advisorsas of 30 Sep 2025 | 2.93m | 5.81% |
| Renaissance Technologies LLCas of 30 Sep 2025 | 2.15m | 4.27% |
| Acadian Asset Management LLCas of 30 Sep 2025 | 2.05m | 4.08% |
| American Century Investment Management, Inc.as of 30 Sep 2025 | 1.48m | 2.94% |
| Dimensional Fund Advisors LPas of 30 Sep 2025 | 1.20m | 2.39% |
| Geode Capital Management LLCas of 30 Sep 2025 | 983.52k | 1.95% |
| Russell Investment Management LLCas of 30 Sep 2025 | 964.69k | 1.91% |
| Connor, Clark & Lunn Investment Management Ltd.as of 30 Sep 2025 | 943.47k | 1.87% |
| Kennedy Capital Management LLCas of 30 Sep 2025 | 867.63k | 1.72% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
